Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + pembrolizumab + plinabulin
- Development stage
- Unknown
- Lead developer
- BeyondSpring
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a triple combination therapy being investigated for metastatic non-small cell lung cancer (NSCLC) patients who have progressed after first-line immune checkpoint inhibitor therapy. The combination leverages the complementary mechanisms of action of each component: docetaxel (a taxane chemotherapy agent), pembrolizumab (a PD-1 inhibitor immunotherapy), and plinabulin (a selective immunomodulating microtubule-binding agent). Plinabulin promotes dendritic cell maturation and enhances anti-tumor T cell responses, potentially overcoming resistance to immunotherapy when combined with pembrolizumab and docetaxel.
- Brand names
- KeytrudaPlinabulinTaxotere
- Other names
- None
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on docetaxel + pembrolizumab + plinabulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + pembrolizumab + plinabulin.